Clinical Trial Update: Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma [Phase 1]

View source ↗

Summary

Phase 1 trial update reports proof of concept for TBio-4101 in combination with lymphodepleting chemotherapy and IL-2 for relapsed/refractory melanoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acral Melanoma
• Conjunctival Melanoma
• Cutaneous Melanoma
• Iris Melanoma
• Melanoma
• Mucosal Melanoma
• Ocular Melanoma
• Uveal Melanoma

Drugs mentioned

• Interleukin-2 (interleukin-2)
• TBio-4101

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Metastatic Melanoma, Unresectable Melanoma | Phase 1 | Status: COMPLETED